Chemotherapy is one of the main modalities in the treatment of cancer, but with the cost of unspecific killing of normal cells and considerable systemic toxicity. Encapsulation of the drug(s) in biodegradable nanoparticles (NPs) has the potential to reduce the side effects and simultaneously keep a high dose of the active drug in the tumor by utilizing the enhanced permeation and retention (EPR) effect, and also through active targeting of the NPs. We are collaborating with different partners who produce NPs, and have obtained promising data using poly(alkyl cyanoacrylate) (PACA) nanoparticles (produced by Sintef) in breast cancer PDX models. The project is performed in close collaboration with Prof Kirsten Sandvig, Department of Molecular Cell Biology, Institute for Cancer Research, and in a newly funded project (Cancer Society, 2019-21) we will actively target the PACA particles to the tumor cells.
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 59 (7), 733-740
ECM1 secreted by HER2-overexpressing breast cancer cells promotes formation of a vascular niche accelerating cancer cell migration and invasion
Lab Invest, 100 (7), 928-944
Drug-Loaded Photosensitizer-Chitosan Nanoparticles for Combinatorial Chemo- and Photodynamic-Therapy of Cancer
Biomacromolecules, 21 (4), 1489-1498